Skip to main content

Market Overview

Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades'

Share:
Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc. (NASDAQ: BIIB) as the 4th cheapest stock in the whole Health Care Select Sector SPDR Fund XLV. The company is scheduled to report quarterly earnings next week.

Analysts expect the company to report quarterly earnings at $3.77 per share on revenue of $2.37 billion.

Karen Firestone of Aureus Asset Management said The Charles Schwab Corporation (NYSE: SCHW) trades at 16 times next year’s earnings.

Charles Schwab reported better-than-expected second-quarter financial results and issued guidance.

Amy Raskin of Chevy Chase Trust named The Goldman Sachs Group, Inc. (NYSE: GS) as her final trade

Goldman Sachs Group reported second-quarter EPS of $3.08, which plunged 60% Y/Y, missing the consensus of $3.18. Net revenues were $10.90 billion, 8% lower than the second quarter of 2022 and 11% lower than the first quarter of 2023.

Don’t forget to check out our premarket coverage here

Price Action: Goldman Sachs shares gained 3% to settle at $350.86, while Charles Schwab shares rose 2.9% to close at $67.94 on Thursday. Biogen shares fell 0.8% to close at $274.70 during Thursday’s session.

Check This Out: Check Out 3 High-Yielding Dividend Stocks In Tech And Telecom Sector From Wall Street's Most Accurate Analysts

Photo: Shutterstock

 

Related Articles (BIIB + GS)

View Comments and Join the Discussion!

Posted-In: Amy Raskin CNBC Halftime Report Final TradesLong Ideas News Markets Media Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com